Literature DB >> 408348

Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in hageman factor-dependent fibrinolysis.

R Mandle, A P Kaplan.   

Abstract

Two molecular forms of prekallikrein can be isolated from pooled normal human plasma. Their approximate molecular weights by sodium dodecyl sulfate-gel electrophoresis are 88,000 and 85,000. The two bands observed are shown to represent prekallikrein by functional, immunochemical, and structural criteria. Both forms are cleaved by activated Hageman factor, they appear to share antigenic determinants, they are not interconvertible upon incubation with activated Hageman factor or kallikrein, and the ratio of kinin-generating, and plasminogen-activating activities of the preparations are independent of the relative proportion of each band. Activated Factor XII converts prekallikrein to kallikrein by limited proteolysis and two disulfide-linked chains designated kallikrein heavy chain (Mr = 52,000) and kallikrein light chains (Mr = 36,000 or 33,000) are formed. The active site is associated with the light chains as assessed by incorporation of [3H]diisopropyl fluorophosphate. No dissociable fragments were observed in the absence of reducing agents. However, kallikrein could digest prekallikrein to diminish its molecular weight by 10,000. In addition, two factors capable of activating plasminogen to plasmin have been isolated; one is identified as kallikrein. The second principle fractionates with Factor XI and is demonstrable in normal and prekallikrein-deficient plasma.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 408348

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  FXII.

Authors:  G Fuhrer; M J Gallimore; W Heller; H E Hoffmeister
Journal:  Blut       Date:  1990-11

Review 2.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

3.  Studies of binding of prekallikrein and Factor XI to high molecular weight kininogen and its light chain.

Authors:  R E Thompson; R Mandle; A P Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

4.  The irradiation of Babesia bovis. 1. The difference in pathogenicity between irradiated and non-irradiated populations.

Authors:  I G Wright; B V Goodger; D F Mahoney
Journal:  Z Parasitenkd       Date:  1980

5.  Rabbit prekallikrein. Purification, biochemical characterization, and mechanism of activation.

Authors:  R J Ulevitch; C G Cochrane; A R Johnston
Journal:  Inflammation       Date:  1980-03       Impact factor: 4.092

6.  Domain structure of bi-functional selenoprotein P.

Authors:  Yoshiro Saito; Noriko Sato; Masaki Hirashima; Gen Takebe; Shigeharu Nagasawa; Kazuhiko Takahashi
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

7.  The activation of the alternative pathway C3 convertase by human plasma kallikrein.

Authors:  R G DiScipio
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

8.  Human plasma kallikrein. A rapid purification method with high yield.

Authors:  H Nagase; A J Barrett
Journal:  Biochem J       Date:  1981-01-01       Impact factor: 3.857

9.  Human plasma kallikrein and C1 inhibitor form a complex possessing an epitope that is not detectable on the parent molecules: demonstration using a monoclonal antibody.

Authors:  A de Agostini; M Schapira; Y T Wachtfogel; R W Colman; S Carrel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

10.  The IgE-dependent release of a Hageman factor cleaving factor from human lung.

Authors:  H L Meier; B Flowers; M Silverberg; A P Kaplan; H H Newball
Journal:  Am J Pathol       Date:  1986-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.